A critical appraisal of MAO-B inhibitors in the treatment of Parkinson’s disease

Author:

Jost Wolfgang H.

Abstract

AbstractSince the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson’s disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson’s disease, an option which is too often not appreciated properly.

Funder

Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes

Publisher

Springer Science and Business Media LLC

Subject

Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology

Reference117 articles.

1. Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kägi G, Raw J, Stefani A, Warnecke T, Jost WH, SYNAPSES Study Investigators Group (2021) A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SYNAPSES Trial. J Parkinsons Dis 11(1):187–198. https://doi.org/10.3233/JPD-219007

2. Bali NR, Salve PS (2020) Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: a nanotheranostic perspective for Parkinsonism. Int J Biol Macromol 164:1006–1024. https://doi.org/10.1016/j.ijbiomac.2020.06.261

3. Bar Am O, Amit T, Youdim MBH (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169–172. https://doi.org/10.1016/j.neulet.2003.10.067

4. Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol 22(8):1184–1191. https://doi.org/10.1111/ene.12724

5. Barone P, Fernandez HH, Ferreira J et al (2013) Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80 (Meeting Abstracts 1): P01.061

Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3